Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
← catalyst calendarSponsored by Bausch & Lomb Incorporated (industry) · BLCO — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
252actual
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-24 | actual | When the study began enrolling |
| Primary completion | 2026-05-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-18 | actual | The whole study's end, after follow-up |
| First posted | 2025-09-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glaucoma
Interventions
- Drug: BL1107 Low dose
- Drug: BL1107 High dose
- Drug: Timolol maleate 0.5%
Primary outcome
what the primary-completion date above is the date OFChange from baseline in visual field mean deviation in the study eye at Day 28/Exit.
measured Assessed at Day 28
Permalink · BLCO's whole pipeline · Catalyst calendar · Every registered study · What changed